Sign up for free insights newsletter
SD

Sartorius Stedim Biotech S.A

SDMHFUnited States

Need professional-grade analysis? Visit stockanalysis.com

$193.00
-1.33%
End of day
Market Cap

$18.78B

P/E Ratio

N/A

Employees

N/A

Dividend Yield

42.00%

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-1.60-0.75-0.15-0.71
Calmar-2.10-0.85-0.17-0.88
Sharpe-1.33-0.54-0.11-0.56
Omega0.560.901.030.87
Martin-4.40-2.41-0.43-2.09
Ulcer14.4010.6611.5111.95

Sartorius Stedim Biotech S.A (SDMHF) Price Performance

Sartorius Stedim Biotech S.A (SDMHF) trades on United States in USD. The company is classified in the Healthcare sector under the Medical Instruments & Supplies industry. The stock currently trades at $193.00, down 1.33% from the previous close.

Over the past year, SDMHF has traded between a low of $173.79 and a high of $259.65. The stock has lost 5.0% over this period. It is currently 25.7% below its 52-week high.

Sartorius Stedim Biotech S.A has a market capitalization of $18.78B and a dividend yield of 42.00%.

About Sartorius Stedim Biotech S.A

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Company Info

Exchange
United States
Currency
USD

Financial Metrics

Revenue (TTM)
$2.97B
EBITDA
$778.10M
Profit Margin
8.95%
EPS (TTM)
3.13
Book Value
48.70

Technical Indicators

52 Week High
$264.30
52 Week Low
$170.00
50 Day MA
$227.68
200 Day MA
$223.83
Beta
1.23

Valuation

Trailing P/E
61.66
Forward P/E
N/A
Price/Sales
6.33
Price/Book
3.96
Enterprise Value
$20.98B